Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor × sargramostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia 27 Lymphoma 26 Lymphoma, Follicular 22 Melanoma 21 Leukemia, Lymphocytic, Chronic, B-Cell 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Multiple Myeloma 15 Lymphoma, Non-Hodgkin 15 Lymphoma, Large B-Cell, Diffuse 14 Leukemia, Myeloid, Acute 14 Lymphoma, Large-Cell, Immunoblastic 13 Breast Neoplasms 13 Lymphoma, Mantle-Cell 12 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12 Neoplasms, Plasma Cell 10 Burkitt Lymphoma 10 Prostatic Neoplasms 9 Neuroblastoma 9 Neoplasm Metastasis 9 Myelodysplastic Syndromes 9 Hodgkin Disease 9 Glioblastoma 9 Lymphoma, B-Cell, Marginal Zone 8 Lung Neoplasms 8 Leukemia, Myeloid, Chronic-Phase 8 Gliosarcoma 7 Carcinoma, Non-Small-Cell Lung 7 Ovarian Neoplasms 6 Central Nervous System Neoplasms 6 Neoplasms 5

Interventions

apatinib 3 vistusertib 2 olaparib 2 camrelizumab 2 atezolizumab 2 Ipilimumab 2 Everolimus 2 trametinib 1 tilsotolimod 1 tazemetostat 1 tazarotene 1 spartalizumab 1 sargramostim 1 sacituzumab govitecan 1 rucaparib 1 roniciclib 1 romiplostim 1 pyrotinib 1 phosphorylethanolamine 1 pemigatinib 1 pembrolizumab 1 pazopanib 1 palbociclib 1 niraparib 1 magrolimab 1 lenvatinib 1 irinotecan sucrosofate 1 famitinib 1 dalpiciclib 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡